BIIB Biogen Inc.

Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)

Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab)
EN
06/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biogen Inc.

Wedbush Research
  • Wedbush Research
 PRESS RELEASE

Biogen Announces Board Chair Transition

Biogen Announces Board Chair Transition Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: BIIB) today announced that the Board of Directors has elected Dr. Maria C. Freire as Chair of the Board of Directors, effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on June 9, 2026. Dr. Freire will succeed Caroline Dorsa who has decided to retire from the Biogen Board of Directors a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch